Global RNA Interference Therapy 麻豆原创 Research Report 2024

Publication ID:

PB501246580

Publication Date:

January 31, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

RNA Interference Therapy, or RNAi Therapy, is a cutting-edge medical approach that utilizes small RNA molecules to selectively silence or regulate targeted genes. This therapeutic method involves introducing synthetic small interfering RNA (siRNA) or microRNA (miRNA) into cells, triggering a natural biological process that inhibits the expression of disease-related genes. RNA Interference Therapy shows promise in treating various conditions, including genetic disorders, viral infections, and certain cancers. By leveraging the specificity of RNA molecules, this therapy holds the potential to revolutionize precision medicine by addressing the root causes of diseases at the genetic level, promoting targeted and personalized treatment strategies.
The global RNA Interference Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The RNA Interference Therapy industry is experiencing a dynamic shift towards precision medicine and targeted treatments. Advancements in understanding genetic mechanisms have fueled a surge in RNAi research and development. The trend emphasizes personalized therapies, with a focus on tackling specific gene-related disorders at the molecular level. Improvements in delivery systems, such as nanoparticle technologies, are enhancing the efficiency and specificity of RNA interference. The growing pipeline of RNAi-based drug candidates, especially in oncology and rare diseases, showcases the increasing interest and investment in this therapeutic approach. Overall, the industry trend leans towards unlocking the full potential of RNA Interference Therapy for precise and effective medical interventions.
This report aims to provide a comprehensive presentation of the global market for RNA Interference Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA Interference Therapy.
Report Scope
The RNA Interference Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA Interference Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA Interference Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Silence Therapeutics
Arrowhead Pharmaceuticals
Janssen Research & Development
Sylentis
Sirnaomics
Dicerna Pharmaceuticals
Alnylam Pharmaceuticals
Silenseed
Vir Biotechnology
OliX Pharmaceuticals
Bio-Path Holdings
Suzhou Ribo Life Science
Segment by Type
siRNA
miRNA
shRNA
piRNA
Segment by Application
Cancer Treatment
Hereditary Disease
Infectious Disease
Nervous System Disease
Diseases of Immune System
Cardiovascular Disease
Metabolic Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA Interference Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global RNA Interference Therapy 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.2.5 piRNA
1.3 麻豆原创 by Application
1.3.1 Global RNA Interference Therapy 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer Treatment
1.3.3 Hereditary Disease
1.3.4 Infectious Disease
1.3.5 Nervous System Disease
1.3.6 Diseases of Immune System
1.3.7 Cardiovascular Disease
1.3.8 Metabolic Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNA Interference Therapy 麻豆原创 Perspective (2019-2030)
2.2 RNA Interference Therapy Growth Trends by Region
2.2.1 Global RNA Interference Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 RNA Interference Therapy Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 RNA Interference Therapy Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 RNA Interference Therapy 麻豆原创 Dynamics
2.3.1 RNA Interference Therapy Industry Trends
2.3.2 RNA Interference Therapy 麻豆原创 Drivers
2.3.3 RNA Interference Therapy 麻豆原创 Challenges
2.3.4 RNA Interference Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNA Interference Therapy Players by Revenue
3.1.1 Global Top RNA Interference Therapy Players by Revenue (2019-2024)
3.1.2 Global RNA Interference Therapy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global RNA Interference Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNA Interference Therapy Revenue
3.4 Global RNA Interference Therapy 麻豆原创 Concentration Ratio
3.4.1 Global RNA Interference Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNA Interference Therapy Revenue in 2023
3.5 RNA Interference Therapy Key Players Head office and Area Served
3.6 Key Players RNA Interference Therapy Product Solution and Service
3.7 Date of Enter into RNA Interference Therapy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 RNA Interference Therapy Breakdown Data by Type
4.1 Global RNA Interference Therapy Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global RNA Interference Therapy Forecasted 麻豆原创 Size by Type (2025-2030)
5 RNA Interference Therapy Breakdown Data by Application
5.1 Global RNA Interference Therapy Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global RNA Interference Therapy Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America RNA Interference Therapy 麻豆原创 Size (2019-2030)
6.2 North America RNA Interference Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America RNA Interference Therapy 麻豆原创 Size by Country (2019-2024)
6.4 North America RNA Interference Therapy 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNA Interference Therapy 麻豆原创 Size (2019-2030)
7.2 Europe RNA Interference Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe RNA Interference Therapy 麻豆原创 Size by Country (2019-2024)
7.4 Europe RNA Interference Therapy 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNA Interference Therapy 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific RNA Interference Therapy 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific RNA Interference Therapy 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific RNA Interference Therapy 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNA Interference Therapy 麻豆原创 Size (2019-2030)
9.2 Latin America RNA Interference Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America RNA Interference Therapy 麻豆原创 Size by Country (2019-2024)
9.4 Latin America RNA Interference Therapy 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNA Interference Therapy 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa RNA Interference Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa RNA Interference Therapy 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa RNA Interference Therapy 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Silence Therapeutics
11.1.1 Silence Therapeutics Company Detail
11.1.2 Silence Therapeutics Business Overview
11.1.3 Silence Therapeutics RNA Interference Therapy Introduction
11.1.4 Silence Therapeutics Revenue in RNA Interference Therapy Business (2019-2024)
11.1.5 Silence Therapeutics Recent Development
11.2 Arrowhead Pharmaceuticals
11.2.1 Arrowhead Pharmaceuticals Company Detail
11.2.2 Arrowhead Pharmaceuticals Business Overview
11.2.3 Arrowhead Pharmaceuticals RNA Interference Therapy Introduction
11.2.4 Arrowhead Pharmaceuticals Revenue in RNA Interference Therapy Business (2019-2024)
11.2.5 Arrowhead Pharmaceuticals Recent Development
11.3 Janssen Research & Development
11.3.1 Janssen Research & Development Company Detail
11.3.2 Janssen Research & Development Business Overview
11.3.3 Janssen Research & Development RNA Interference Therapy Introduction
11.3.4 Janssen Research & Development Revenue in RNA Interference Therapy Business (2019-2024)
11.3.5 Janssen Research & Development Recent Development
11.4 Sylentis
11.4.1 Sylentis Company Detail
11.4.2 Sylentis Business Overview
11.4.3 Sylentis RNA Interference Therapy Introduction
11.4.4 Sylentis Revenue in RNA Interference Therapy Business (2019-2024)
11.4.5 Sylentis Recent Development
11.5 Sirnaomics
11.5.1 Sirnaomics Company Detail
11.5.2 Sirnaomics Business Overview
11.5.3 Sirnaomics RNA Interference Therapy Introduction
11.5.4 Sirnaomics Revenue in RNA Interference Therapy Business (2019-2024)
11.5.5 Sirnaomics Recent Development
11.6 Dicerna Pharmaceuticals
11.6.1 Dicerna Pharmaceuticals Company Detail
11.6.2 Dicerna Pharmaceuticals Business Overview
11.6.3 Dicerna Pharmaceuticals RNA Interference Therapy Introduction
11.6.4 Dicerna Pharmaceuticals Revenue in RNA Interference Therapy Business (2019-2024)
11.6.5 Dicerna Pharmaceuticals Recent Development
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Company Detail
11.7.2 Alnylam Pharmaceuticals Business Overview
11.7.3 Alnylam Pharmaceuticals RNA Interference Therapy Introduction
11.7.4 Alnylam Pharmaceuticals Revenue in RNA Interference Therapy Business (2019-2024)
11.7.5 Alnylam Pharmaceuticals Recent Development
11.8 Silenseed
11.8.1 Silenseed Company Detail
11.8.2 Silenseed Business Overview
11.8.3 Silenseed RNA Interference Therapy Introduction
11.8.4 Silenseed Revenue in RNA Interference Therapy Business (2019-2024)
11.8.5 Silenseed Recent Development
11.9 Vir Biotechnology
11.9.1 Vir Biotechnology Company Detail
11.9.2 Vir Biotechnology Business Overview
11.9.3 Vir Biotechnology RNA Interference Therapy Introduction
11.9.4 Vir Biotechnology Revenue in RNA Interference Therapy Business (2019-2024)
11.9.5 Vir Biotechnology Recent Development
11.10 OliX Pharmaceuticals
11.10.1 OliX Pharmaceuticals Company Detail
11.10.2 OliX Pharmaceuticals Business Overview
11.10.3 OliX Pharmaceuticals RNA Interference Therapy Introduction
11.10.4 OliX Pharmaceuticals Revenue in RNA Interference Therapy Business (2019-2024)
11.10.5 OliX Pharmaceuticals Recent Development
11.11 Bio-Path Holdings
11.11.1 Bio-Path Holdings Company Detail
11.11.2 Bio-Path Holdings Business Overview
11.11.3 Bio-Path Holdings RNA Interference Therapy Introduction
11.11.4 Bio-Path Holdings Revenue in RNA Interference Therapy Business (2019-2024)
11.11.5 Bio-Path Holdings Recent Development
11.12 Suzhou Ribo Life Science
11.12.1 Suzhou Ribo Life Science Company Detail
11.12.2 Suzhou Ribo Life Science Business Overview
11.12.3 Suzhou Ribo Life Science RNA Interference Therapy Introduction
11.12.4 Suzhou Ribo Life Science Revenue in RNA Interference Therapy Business (2019-2024)
11.12.5 Suzhou Ribo Life Science Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Silence Therapeutics
Arrowhead Pharmaceuticals
Janssen Research & Development
Sylentis
Sirnaomics
Dicerna Pharmaceuticals
Alnylam Pharmaceuticals
Silenseed
Vir Biotechnology
OliX Pharmaceuticals
Bio-Path Holdings
Suzhou Ribo Life Science

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.